| Trial ID: | L6302 |
| Source ID: | NCT00551356
|
| Associated Drug: |
Insulin Lispro Mix 25
|
| Title: |
Lispro Mix 25 vs. Glargine in Type 2 Diabetics
|
| Acronym: |
IOOL
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Insulin lispro mix 25|DRUG: Glargine
|
| Outcome Measures: |
Primary: Change from baseline to endpoint in 2h postprandial blood glucose excursion after breakfast, 16 weeks or end of study. | Secondary: Hemoglobin A1c measured at endpoint, 16 weeks or end of study.|Change of hemoglobin A1c from baseline to endpoint, 16 weeks or end of study.|Glycemic control as determined by self-monitored blood glucose concentrations, 16 weeks or end of study.|The incidence and rate of self-reported hypoglycemic episodes, 16 weeks or end of study.|Body mass index (BMI), 16 weeks or end of study.|Body weight, 16 weeks or end of study.|Total Insulin Doses, 16 weeks or end of study.
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
53
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-11
|
| Completion Date: |
2003-07
|
| Results First Posted: |
|
| Last Update Posted: |
2007-10-31
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico
|
| URL: |
https://clinicaltrials.gov/show/NCT00551356
|
